ISRCTN60271166已完成未知
A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds
TG Eakin Limited (UK)0 个研究点目标入组 40 人开始时间: 2005年6月15日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •All patients presenting superficial/partial thickness wounds which could or would normally be treated with a 'hydrocolloid' wound dressing, and who are not precluded by the exclusion criteria below, will be invited to participate in this clinical trial.
排除标准
- •Patients will be excluded from the trial under the following circumstances:
- •1. Wound is >5 cm length or breadth
- •2. Wound is >0.5 cm depth
- •3. Wound involving muscle, tendon or bone
- •4. Wound infection is suspected
- •5. Where informed consent is withheld
- •6. Where patients are unable to give informed consent due to legal incompetence, unless informed consent is available from a responsible relative or guardian
- •7. Where, in the physician's opinion, inclusion in the trial is not advised
研究者
相似试验
尚未招募
Unknown
Feasibility clinical trial to evaluate initial safety and efficacy of treatment for pain relief using Focused ultrasound stimulator system ‘IMD20’ in patients with Lateral Epicondylitis by comparing pain scores using the NRSDiseases of the musculoskeletal system and connective tissueKCT0009381IMGT30
尚未招募
2 期
The effect of chitosan spray on bleeding and wound healing following tear duct surgery.ACTRN12609001028291South Australian Institute of Ophthalmology26
招募中
2 期
A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers2024-518757-42-00Xintela AB6
尚未招募
Unknown
A Comparative Study of a Novel Venous Hemostasis Device Utilizing Collagen Patches and the Figure-of-Eight Suture Hemostasis.ArrhythmiaJPRN-UMIN000052235Tokyo Medical and Dental University Hospital44
已完成
不适用
A phase I randomised single-blinded single-centre study comparing doses of Plasmodium falciparum chimeric protein 2.9 (PfCP-2.9) recombinant vaccine adjuvanted with Montanide ISA 720 for safety and immunogenicityInfections and InfestationsMalariaISRCTN66850051World Health Organization (WHO) (Switzerland)52
